Psychopharmacology

, Volume 49, Issue 1, pp 101–107 | Cite as

Clinical significance of plasma chlorpromazine levels

II. Plasma levels of the drug, some of tis metabolites and prolactin in patients receiving long-term phenothiazine treatment
  • T. Kolakowska
  • D. H. Wiles
  • M. G. Gelder
  • A. S. McNeilly
Human Pharmacology
  • 56 Downloads

Abstract

Plasma levels of chlorpromazine (CPZ), 3 of its metabolites and prolacin were measured repeatedly in 18 chronic schizophrenic patients. The patients were studied while on chronic phenothiazine medication (chlorpromazine in 8, other phenothiazines in 10), during 4–6 weeks on placebo and during 6–12 weeks of CPZ treatment. The findings were compared with those obtained during acute CPZ treatment in patients who had received similar CPZ doses but no previous long-term phenothiazine medication.

Plasma CPZ levels were similar in the chronic and the acute groups and so was their relation to dose. In neither group was therapeutic effect related to plasma CPZ level. In these chronic patients, in contrast to findings during acute CPZ treatment, neither prolactin level nor the appearance of parkinsonian symptoms was related to plasma drug level. In the chronic group both these effects were less pronounced during the period on CPZ which followed the placebo than were the corresponding effects during CPZ treatment in the acute group. Since plasma CPZ levels of the two groups were similar, these differences may be due to an acquired tolerance of the nervous system to some of the antidopaminergic effects of the drug.

Key words

Chlorpromazine Chlorpromazine metabolites Prolactin Chronic phenothiazine treatment Parkinsonian symptoms Tolerance 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andén, N.-E.: Dopamine turnover in the corpus striatum and the limbic system after treatment with neuroleptic and anticholinergic drugs. J. Pharm. Pharmacol. 24, 905–906 (1972)Google Scholar
  2. Beumont, P. J. V., Corker, C. S., Friesen, H. G., Kolakowska, T., Mandelbrote, B. M., Marshall, J., Murray, M. A. F., Wiles, D. H.: The effects of phenothiazines on endocrine function: Effects in men and postmenopausal women. Brit. J. Psychiat. 124, 420–430 (1974)Google Scholar
  3. Bowers, M. B.: 5 HIAA and HVA following probenecid in acute psychotic patients treated with phenothiazine. Psychopharmacologia (Berl.) 28, 309–318 (1973)Google Scholar
  4. Bowers, M. B., Rositis, A.: Regional differences in homovanillic acid concentration after acute and chronic administration of antipsychotic drugs. J. Pharm. Pharmacol. 26, 743–745 (1974)Google Scholar
  5. Curry, S. H.: Determination of nanogram quantities of chlorpromazine and some of its metabolites using gas liquid chromatography with an electron capture detector. Analyt. Chem. 40, 1251–1255 (1968)Google Scholar
  6. Curry, S. H., Marshall, J. H. L.: Plasma levels of chlorpromazine and some of its relatively non-polar metabolites. Life Sci. 7, 9–17 (1968)Google Scholar
  7. Curry, S. H., Marshall, J. H. L., Davis, J. M., Janowsky, D. S.: Chlorpromazine plasma levels and effects. Arch. gen. Psychiat. 22, 289–296 (1970)Google Scholar
  8. Fyro, B. O., Wode-Helgodt, B., Borg, S., Sedvall, G.: The effect of chlorpromazine on homovanillic acid levels in cerebrospinal fluid of schizophrenic patients. Psychopharmacologia (Berl.) 35, 287–294 (1974)Google Scholar
  9. Goodwin, F. K., Post, R. M., Sack, R. L.: Clinical evidence for neurochemical adaptation to psychotropic drugs. In: Neurobiological mechanisms of adaptation and behaviour. A. J. Mandell, ed., pp. 33–45. New York: Raven Press 1975Google Scholar
  10. Harris, A. D., Letemendia, F. J. J., Willems, P. J. A.: A rating scale of the mental state: for use in the chronic population of psychiatric hospital. Brit. J. Psychiat. 113, 941–949 (1967)Google Scholar
  11. Hwang, P., Gyuda, H., Friesen, H.: Radioimmunoassay of human prolactin. Proc. nat. Acad. Sci. (Wash.) 68, 1902–1906 (1971)Google Scholar
  12. McNeilly, A. S., Hagen, C.: Prolactin, TSH, LH, and FSH responses in a combined LHRH/TRH test a different stages of the menstrual cycle. Clin. Endocr. 3, 427–435 (1974)Google Scholar
  13. MacKay, A. V. P., Healey, A. F., Baker, J.: The relationship of plasma chlorpromazine to its 7-hydroxy and sulphoxide metabolites in a large population of chronic schizophrenics. Brit. J. Clin. Pharmacol. 1, 425–430 (1974)Google Scholar
  14. O'Keeffe, R., Sharman, D. F., Vogt, M.: Effects of drugs used in psychoses on cerebral dopamine metabolism. Brit. J. Pharmacol. 38, 287–304 (1970)Google Scholar
  15. Rivera-Calimlim, L., Castaneda, L., Lasagna, L.: Effects of mode of management of plasma chlorpromazine in psychiatric patients. Clin. Pharmacol. Ther. 14, 979–985 (1974)Google Scholar
  16. Sakalis, G., Curry, S. H., Mould, G. O., Lader, M. H.: Physiologic and clinical effects of chlorpromazine and their relationship to plasma level. Clin. Pharmacol. Ther. 13, 931–946 (1972)Google Scholar
  17. Sayers, A. C., Burki, H. R., Ruch, W., Asper, H.: Neuroleptic induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesia. Effects of clozapine haloperidol, loxapine and chlorpromazine. Psychopharmacologia (Berl.) 41, 97–104 (1975)Google Scholar
  18. Simpson, G. H., Angus, J. W. S.: A rating scale for extrapyramidal side-effects. Acta psychiat. scand. Suppl. 212, 11–19 (1970)Google Scholar
  19. Wiesel, F. A., Alfredson, G., Likwornik, V., Sedvall, G.: A relation between drug concentration in brain and striatal homovanillic acid in chlorpromazine treated rats. Life Sci. 16, 1145–1156 (1975)Google Scholar
  20. Wiles, D. H., Kolakowska, T., McNeilly, A. S., Mandelbrote, B. M., Gelder, M. G.: Clinical significance of plasma chlorpromazine levels: I. Plasma levels of the drug, some of its metabolites and prolactin during acute treatment. Psychol. Med. (in press, 1976)Google Scholar

Copyright information

© Springer-Verlag 1976

Authors and Affiliations

  • T. Kolakowska
    • 1
  • D. H. Wiles
    • 1
  • M. G. Gelder
    • 1
  • A. S. McNeilly
    • 2
  1. 1.Department of Psychiatry, Littlemore Hospital Research UnitUniversity of OxfordOxford
  2. 2.Department of Chemical PathologySt. Bartholomew's HospitalLondon

Personalised recommendations